Ternary Therapeutics Ltd

Ternary Therapeutics Ltd, based in London, UK, is focused on pioneering molecular glue discovery, employing innovative computational design methodologies to tackle intricate biological challenges in drug development. Founded in 2024, Ternary Therapeutics Ltd operates out of London, UK, specializing in the creation of molecular glue degraders and activators. The company has received GBP 3. 6 million in Seed funding as of March 16, 2026, led by Daphni, with participation from Future Planet Capital, Pace Ventures Enigma, and i&i Bio.

The founder's background includes previous ventures in the biotech sector, although specific details are not available. Ternary Therapeutics has established one deal to date, positioning itself within a competitive market for pharmaceutical innovations. Ternary Therapeutics specializes in the development of molecular glue degraders and activators, utilizing a proprietary computational design platform to drive innovation. Their technology addresses complex biological challenges by identifying hot spots on protein surfaces for ternary complex formation.

This facilitates the rational design of therapeutic agents to be used in drug discovery efforts. Targeting the pharmaceutical and biotechnology sectors, Ternary Therapeutics serves a global client base that includes research institutions and biotech firms, focusing on various therapeutic indications across North America, Europe, and Asia. Ternary Therapeutics generates revenue primarily through partnerships and collaborations with the pharmaceutical industry, engaging in B2B transactions with biotech companies and research institutions. Their revenue structure includes licensing agreements and project-based collaborations, allowing access to their innovative technology for molecular glue design.

Pricing is tailored to project complexity and duration, negotiated per collaboration, thus driving revenue through these specialized agreements. Following its recent Seed funding of GBP 3. 6 million on March 16, 2026, Ternary Therapeutics plans to expand its computational and laboratory teams to advance its lead programmes towards preclinical development. The company aims to introduce new products designed to enhance drug discovery and plans to target expansion in North America and Asia by 2027, leveraging its growing expertise and resources to penetrate these key markets.